Additionally, survivin peptide vaccine was considered to be a very potent immunotherapeutic regimen and the results from randomized phase II trial in patients with HLA A24-positive pancreatic adenocarcinoma were recently published [34]. This evidence concerns the gene BIRC5 and pancreatic adenocarcinoma.